Sexual Dysfunction in Schizophrenia: A Narrative Review of the Mechanisms and Clinical Considerations

IF 1.2 Q4 PSYCHIATRY
Amber N. Edinoff, Catherine A. Nix, J. Fort, Jeanna Kimble, Ryan D. Guedry, G. Thomas, E. Cornett, A. Kaye, A. Kaye
{"title":"Sexual Dysfunction in Schizophrenia: A Narrative Review of the Mechanisms and Clinical Considerations","authors":"Amber N. Edinoff, Catherine A. Nix, J. Fort, Jeanna Kimble, Ryan D. Guedry, G. Thomas, E. Cornett, A. Kaye, A. Kaye","doi":"10.3390/psychiatryint3010003","DOIUrl":null,"url":null,"abstract":"Psychiatric disorders, in general, have a high prevalence of sexual problems, whether from the psychopathology of the disorder itself, pre-existing or co-morbid sexual disorder or from side effects of the treatment for mental disorders. Many patients report an already existing sexual dysfunction at the onset of diagnosis. The risk association for developing sexual dysfunction in patients with schizophrenia includes antipsychotic use and resulting hyperprolactinemia, age, gender, and disease severity. Medication side effects lead to nonadherence, and relapses lead to structural changes in the brain, treatment resistance, and worsening of symptoms. Findings in certain studies propose serum prolactin and thyroid-stimulating hormone measurement as a tool for assessing patients with schizophrenia for sexual dysfunction. Regarding specific symptoms, females especially reported decreased desire at baseline and galactorrhea after treatment. The findings of this review, therefore, suggest that sexual dysfunction may be present in patients with schizophrenia before starting antipsychotic treatment and that patients, especially those who are female, are likely to develop hyperprolactinemia with antipsychotic treatment. Aripiprazole may be an emergent treatment for sexual dysfunction in those who use antipsychotics. It is important for patients to consider sexual dysfunction prior to prescribing antipsychotics. Since sexual dysfunction can impact a patient’s quality of life and affect treatment adherence, it is important for physicians to be aware and monitor patients for symptoms.","PeriodicalId":93808,"journal":{"name":"Psychiatry international","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatry international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/psychiatryint3010003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 3

Abstract

Psychiatric disorders, in general, have a high prevalence of sexual problems, whether from the psychopathology of the disorder itself, pre-existing or co-morbid sexual disorder or from side effects of the treatment for mental disorders. Many patients report an already existing sexual dysfunction at the onset of diagnosis. The risk association for developing sexual dysfunction in patients with schizophrenia includes antipsychotic use and resulting hyperprolactinemia, age, gender, and disease severity. Medication side effects lead to nonadherence, and relapses lead to structural changes in the brain, treatment resistance, and worsening of symptoms. Findings in certain studies propose serum prolactin and thyroid-stimulating hormone measurement as a tool for assessing patients with schizophrenia for sexual dysfunction. Regarding specific symptoms, females especially reported decreased desire at baseline and galactorrhea after treatment. The findings of this review, therefore, suggest that sexual dysfunction may be present in patients with schizophrenia before starting antipsychotic treatment and that patients, especially those who are female, are likely to develop hyperprolactinemia with antipsychotic treatment. Aripiprazole may be an emergent treatment for sexual dysfunction in those who use antipsychotics. It is important for patients to consider sexual dysfunction prior to prescribing antipsychotics. Since sexual dysfunction can impact a patient’s quality of life and affect treatment adherence, it is important for physicians to be aware and monitor patients for symptoms.
精神分裂症的性功能障碍:机制和临床考虑的叙述性回顾
一般来说,精神障碍的性问题发生率很高,无论是由于精神障碍本身的精神病理学、先前存在的或共病性障碍,还是由于精神障碍治疗的副作用。许多患者在诊断时报告已经存在性功能障碍。精神分裂症患者发生性功能障碍的风险关联包括抗精神病药物的使用及其导致的高泌乳素血症、年龄、性别和疾病严重程度。药物副作用导致不依从,复发导致大脑结构改变、治疗抵抗和症状恶化。某些研究结果提出血清催乳素和促甲状腺激素的测量作为评估精神分裂症患者性功能障碍的工具。关于具体症状,女性尤其报告在基线时性欲下降和治疗后溢乳。因此,本综述的研究结果表明,精神分裂症患者在开始抗精神病药物治疗之前可能存在性功能障碍,并且患者,特别是女性患者,在接受抗精神病药物治疗后很可能出现高泌乳素血症。阿立哌唑可能是抗精神病药物患者性功能障碍的紧急治疗方法。患者在开抗精神病药前考虑性功能障碍是很重要的。由于性功能障碍会影响患者的生活质量并影响治疗依从性,因此医生了解并监测患者的症状非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
0
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信